S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:HOOK

Hookipa Pharma (HOOK) Stock Price, News & Analysis

$0.71
-0.01 (-1.39%)
(As of 03/28/2024 ET)
Today's Range
$0.71
$0.74
50-Day Range
$0.61
$0.81
52-Week Range
$0.41
$2.05
Volume
375,874 shs
Average Volume
558,526 shs
Market Capitalization
$59.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.17

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
625.7% Upside
$5.17 Price Target
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Hookipa Pharma in the last 14 days
Based on 28 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

413th out of 938 stocks

Pharmaceutical Preparations Industry

188th out of 417 stocks

HOOK stock logo

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

HOOK Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
HOOKIPA Pharma Inc HOOK
Hookipa Pharma Inc (HOOK)
HOOKIPA Pharma To Cut Jobs Following Collaboration Termination By Roche
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.17
High Stock Price Target
$6.50
Low Stock Price Target
$4.00
Potential Upside/Downside
+625.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-81,580,000.00
Net Margins
-405.28%
Pretax Margin
-403.46%

Debt

Sales & Book Value

Annual Sales
$20.13 million
Book Value
$1.87 per share

Miscellaneous

Free Float
79,064,000
Market Cap
$59.77 million
Optionable
Optionable
Beta
1.03
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price target for 2024?

3 analysts have issued 12 month target prices for Hookipa Pharma's stock. Their HOOK share price targets range from $4.00 to $6.50. On average, they expect the company's share price to reach $5.17 in the next twelve months. This suggests a possible upside of 625.7% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2024?

Hookipa Pharma's stock was trading at $0.81 at the beginning of the year. Since then, HOOK shares have decreased by 12.1% and is now trading at $0.7120.
View the best growth stocks for 2024 here
.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 333,400 shares, an increase of 11.3% from the February 29th total of 299,500 shares. Based on an average daily volume of 2,410,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the shares of the company are sold short.
View Hookipa Pharma's Short Interest
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its earnings results on Friday, November, 12th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.09. The company earned $3.87 million during the quarter, compared to analyst estimates of $5.24 million. Hookipa Pharma had a negative net margin of 405.28% and a negative trailing twelve-month return on equity of 72.30%. During the same period in the prior year, the company earned ($0.53) earnings per share.

What other stocks do shareholders of Hookipa Pharma own?
When did Hookipa Pharma IPO?

Hookipa Pharma (HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Vanguard Group Inc. (2.52%), Royal Bank of Canada (0.26%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr.
View institutional ownership trends
.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners